170 related articles for article (PubMed ID: 38028423)
1. Long-term benefit after allergen immunotherapy to HDM in elderly patients with allergic rhinitis.
Bożek A; Bogacz-Piaseczyńska A; Miodońska M; Sadowska D
Postepy Dermatol Alergol; 2023 Oct; 40(5):688-692. PubMed ID: 38028423
[TBL] [Abstract][Full Text] [Related]
2. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
3. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir.
Baba SM; Rasool R; Gull A; Qureshi TA; Beigh AH; Qadri Q; Shah ZA
Front Immunol; 2021; 12():723814. PubMed ID: 34721385
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
Huang HH; Xu C; Liu L; Chai RN
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859
[No Abstract] [Full Text] [Related]
6. Long-term effects of allergen sublingual immunotherapy.
Bozek A; Foks A; Trzaska K; Canonica GW
Postepy Dermatol Alergol; 2020 Dec; 37(6):943-947. PubMed ID: 33603614
[TBL] [Abstract][Full Text] [Related]
7. Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial.
Bożek A; Kołodziejczyk K; Kozłowska R; Canonica GW
Clin Transl Allergy; 2017; 7():43. PubMed ID: 29214012
[TBL] [Abstract][Full Text] [Related]
8. Specific IgE and IgG4 Profiles of House Dust Mite Components in Allergen-Specific Immunotherapy.
Yang L; Yang Y; Xu Q; Zhang W; Jiang Q; Li W; Wang Y; Ma D; Lin X; Sun B; Zhu R
Front Immunol; 2021; 12():786738. PubMed ID: 35197963
[TBL] [Abstract][Full Text] [Related]
9. New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ
Vitiello G; Maltagliati L; Rossi O
Clin Mol Allergy; 2020; 18():10. PubMed ID: 32536827
[TBL] [Abstract][Full Text] [Related]
10. Comparison of rush-subcutaneous and sublingual immunotherapy with house dust mite extract for pediatric allergic rhinitis: A prospective cohort study.
Hamada M; Saeki K; Tanaka I
Allergol Int; 2023 Oct; 72(4):573-579. PubMed ID: 36918306
[TBL] [Abstract][Full Text] [Related]
11. Suppression function against environmental dust exposure after Dermatophagoides pteronyssinus immunotherapy is associated with production of specific and cross-reactive immunoglobulin G4.
Feng M; Luo T; Xian M; Shi X; Qin R; Zeng X; Su Q; Li J
Clin Exp Allergy; 2022 Jul; 52(7):878-887. PubMed ID: 34962673
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of AIT in the elderly population.
Bożek A
Curr Opin Allergy Clin Immunol; 2023 Aug; 23(4):341-345. PubMed ID: 37357782
[TBL] [Abstract][Full Text] [Related]
13. State of the Art: Development of a Sublingual Allergy Immunotherapy Tablet for Allergic Rhinitis in Japan.
Ohashi-Doi K; Lund K; Mitobe Y; Okamiya K
Biol Pharm Bull; 2020; 43(1):41-48. PubMed ID: 31902930
[TBL] [Abstract][Full Text] [Related]
14. Allergen Immunotherapy in Asthma.
Nakagome K; Nagata M
Pathogens; 2021 Oct; 10(11):. PubMed ID: 34832562
[TBL] [Abstract][Full Text] [Related]
15. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
[TBL] [Abstract][Full Text] [Related]
16. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
[TBL] [Abstract][Full Text] [Related]
17. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
[TBL] [Abstract][Full Text] [Related]
18. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting.
Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M
Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466
[TBL] [Abstract][Full Text] [Related]
19. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.
Eifan AO; Calderon MA; Durham SR
Expert Opin Biol Ther; 2013 Nov; 13(11):1543-56. PubMed ID: 24099116
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of subcutaneous house dust mite immunotherapy in patients with moderate to severe allergic rhinitis.
Valero A; Ibáñez-Echevarría E; Vidal C; Raducan I; Castelló Carrascosa JV; Sánchez-López J
Immunotherapy; 2022 Jun; 14(9):683-694. PubMed ID: 35465692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
